Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
暂无分享，去创建一个
R. Bhisitkul | C. Awh | H. Shapiro | D. Boyer | A. Antoszyk | N. Acharya
[1] Gerald Liew,et al. Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.
[2] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[3] Michael Stur,et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. , 2003, American journal of ophthalmology.
[4] P. D. de Jong,et al. Increased expression of angiogenic growth factors in age-related maculopathy , 1997, The British journal of ophthalmology.
[5] D. Eliott,et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. , 1996, American journal of ophthalmology.
[6] S. Seregard,et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. , 1996, Investigative ophthalmology & visual science.
[7] D. Hinton,et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. , 1996, Investigative ophthalmology & visual science.